MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology _ Genomics, Genetic Testing, Gene & DNA Sequencing, NGS (Next Generation Sequencing) Companies
Adverum Biotechnologies, Inc. (NASDAQ: ADVM), previously, Avalanche Biotechnologies
Organization & Developments: Adverum
Parents
Adverum Biotechnologies, Inc. (NASDAQ: ADVM), previously, Avalanche Biotechnologies
Children
*The company's approach is based on its adeno-associated virus (AAV)-based directed evolution platform that seeks to induce sustained expression of therapeutic proteins.
2017: Adverum: Why This ~$3.50 Biotech 'Busted IPO' Gets Our 'Thumbs Up'_seekingalpha.com
2018: Adverum Biotechnologies: Gene Therapy Company And Our New Buy_seekingalpha.com
2019: Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path_seekingalpha.com
2019: Updated Investment Thesis On Adverum Biotechnologies_seekingalpha.com
2020: Assessing Adverum
2021: Adverum Biotechnologies: One Adverse Event Too Many
2021: Adverum Confirms Patient Loses Sight in Eye Treated with Its Gene Therapy
2022: Adverum lays off 78 employees, bets it all on embattled eye treatment
2024: Adverum Biotechnologies Announces Positive 52-Week LUNA and Provides Key Pivotal Program Design Elements
2024: Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients_ seekingalpha.com
2025: Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
Jumps
*Key People: Adverum
Finance & Acquisitions: Adverum